Quick Answer
CASI Pharmaceuticals, Inc. reported Total Revenue of $28.54 million for fiscal year 2024.
CASI Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $28.54M -15.8% |
$33.88M -21.4% |
$43.11M +42.9% |
$30.17M +99.2% |
$15.14M | — |
| Revenue (ASC 606) | $28.54M -15.8% |
$33.88M -11.0% |
$38.05M +26.7% |
$30.02M +100.1% |
$15.00M | — |
| Net Income | -$39.26M -45.6% |
-$26.96M +34.3% |
-$41.01M -11.9% |
-$36.65M +24.1% |
-$48.29M | — |
| Diluted EPS | -$2.56 -26.7% |
-$2.02 +32.9% |
-$3.01 -11.9% |
-$2.69 +38.4% |
-$4.37 | — |
| Total Assets | $53.67M -28.7% |
$75.27M -21.8% |
$96.23M -30.4% |
$138.30M | — | — |
| Cash and Equivalents | $13.47M -21.2% |
$17.08M -63.7% |
$47.11M +21.7% |
$38.70M | — | — |
| Long-Term Debt | — | $18.89M | — | — | — | — |
| Stockholders Equity | $1.85M -92.3% |
$24.16M -45.8% |
$44.57M -47.3% |
$84.50M +3.6% |
$81.54M +11.7% |
$73.00M |
| R&D Expense | $8.92M -9.6% |
$9.86M -38.4% |
$16.00M | — | — | — |
| Operating Income | -$39.62M -58.0% |
-$25.08M +26.3% |
-$34.03M +18.0% |
-$41.52M +21.3% |
-$52.78M | — |
| Gross Profit | $11.15M -44.4% |
$20.05M -26.5% |
$27.28M +54.9% |
$17.61M +212.6% |
$5.63M | — |
| Shares Outstanding | 15.49M +15.8% |
13.38M -0.6% |
13.46M -3.7% |
13.98M | — | — |
- CASI Pharmaceuticals, Inc. reported Total Revenue of $28.54 million for fiscal year 2024.
- CASI Pharmaceuticals, Inc. showed a decrease of -15.8% in Total Revenue compared to the prior fiscal year.
- CASI Pharmaceuticals, Inc. reported Revenue (ASC 606) of $28.54 million for fiscal year 2024.
- CASI Pharmaceuticals, Inc. showed a decrease of -15.8% in Revenue (ASC 606) compared to the prior fiscal year.
- CASI Pharmaceuticals, Inc. reported Net Income of -$39.26 million for fiscal year 2024.
- CASI Pharmaceuticals, Inc. showed a decrease of -45.6% in Net Income compared to the prior fiscal year.
- CASI Pharmaceuticals, Inc. reported Diluted EPS of $2.56 per share (loss) for fiscal year 2024.
- CASI Pharmaceuticals, Inc. showed a decrease of -26.7% in Diluted EPS compared to the prior fiscal year.
- CASI Pharmaceuticals, Inc. reported Total Assets of $53.67 million for fiscal year 2024.
- CASI Pharmaceuticals, Inc. showed a decrease of -28.7% in Total Assets compared to the prior fiscal year.
- CASI Pharmaceuticals, Inc. reported Cash and Equivalents of $13.47 million for fiscal year 2024.
- CASI Pharmaceuticals, Inc. showed a decrease of -21.2% in Cash and Equivalents compared to the prior fiscal year.
- CASI Pharmaceuticals, Inc. reported Long-Term Debt of $18.89 million for fiscal year 2023.
- CASI Pharmaceuticals, Inc. reported Stockholders Equity of $1.85 million for fiscal year 2024.
- CASI Pharmaceuticals, Inc. showed a decrease of -92.3% in Stockholders Equity compared to the prior fiscal year.
- CASI Pharmaceuticals, Inc. reported R&D Expense of $8.92 million for fiscal year 2024.
- CASI Pharmaceuticals, Inc. showed a decrease of -9.6% in R&D Expense compared to the prior fiscal year.
- CASI Pharmaceuticals, Inc. reported Operating Income of -$39.62 million for fiscal year 2024.
- CASI Pharmaceuticals, Inc. showed a decrease of -58.0% in Operating Income compared to the prior fiscal year.
- CASI Pharmaceuticals, Inc. reported Gross Profit of $11.15 million for fiscal year 2024.
- CASI Pharmaceuticals, Inc. showed a decrease of -44.4% in Gross Profit compared to the prior fiscal year.
- CASI Pharmaceuticals, Inc. reported Shares Outstanding of 15.49 million shares for fiscal year 2024.
- CASI Pharmaceuticals, Inc. showed an increase of +15.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: